QRL-201, an experimental therapy from Quralis, slowed disease progression by 50% in people with amyotrophic lateral sclerosis (ALS) who received one of the tested doses of the therapy, according to final results from a Phase 1/2 clinical trial. The findings come from the dose-range finding phase of the…
News
Precision Neuroscience and the nonprofit Team Gleason are partnering to give people with amyotrophic lateral sclerosis (ALS), their families, and caregivers a direct role in shaping a brain-computer interface (BCI). Precision is developing the BCI system for people with severe paralysis caused by conditions including ALS and…
Elevated blood levels of neurofilament light chain (NfL), a protein released when nerve cells are damaged, are associated with an increased risk of developing amyotrophic lateral sclerosis (ALS), potentially years before symptoms emerge, according to a new study. The analysis, which included more than 52,000 people in the U.K.,…
After showing encouraging early signs of disease stabilization and functional improvements in a small study, an experimental infusion therapy for amyotrophic lateral sclerosis (ALS) is advancing to a new, larger clinical trial in Australia. Nuerve announced in a company press release…
The recent Muscular Dystrophy Association (MDA) Engage Community Seminar with Stanford Medicine was packed with educational sessions, but some of the most meaningful takeaways for participants were about connection and community. “That’s what makes MDA Engage Symposium so special,” Marissa Lozano, director of community education at the MDA,…
PRC-Saltillo and Team Gleason are partnering to help people with amyotrophic lateral sclerosis (ALS) maintain communication and connections with family, friends, and their communities as the disease progresses. Under the collaboration, PRC-Saltillo will contribute its expertise in speech-generating technology and augmentative and alternative communication (AAC), while Team…
Some people with amyotrophic lateral sclerosis (ALS) experience subtle signs of the disease, such as pain and motor problems, in the years before they are diagnosed. The findings add to growing evidence that ALS may have a prodromal phase, a period in which people start to experience biological changes…
People with amyotrophic lateral sclerosis (ALS) may share genetic roots with people who have other neurodegenerative conditions, including frontotemporal dementia (FTD), even when no family connection is known, a new study suggests. The findings highlight the genetic overlap across the ALS-FTD disease spectrum and suggest that conventional family histories may…
A pivotal Phase 2/3 clinical trial comparing the experimental oral therapy CB03-154 with a placebo in people with amyotrophic lateral sclerosis (ALS) has completed enrollment in China, developer Zhimeng Biopharma announced. China’s Center for Drug Evaluation (CDE) cleared the trial to begin last year. It…
President Donald Trump has signed into law legislation to renew the Accelerating Access to Critical Therapies (ACT) for amyotrophic lateral sclerosis (ALS), a federal program aimed at supporting ALS research and helping patients access promising experimental therapies. The original ACT for ALS was signed into law in 2021…
Recent Posts
- Reflecting on the early signs of my husband’s ALS
- Experimental ALS treatment slows disease progression by 50% in trial
- ALS community to have a say in brain-computer interface development
- Blood NfL levels linked to higher ALS risk years before onset
- After promising early results, ALS drug moves toward new, larger trial